BTIG Research Reaffirms Buy Rating for Quotient Limited (QTNT)

BTIG Research restated their buy rating on shares of Quotient Limited (NASDAQ:QTNT) in a research note released on Wednesday. They currently have a $12.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on QTNT. Jefferies Group LLC dropped their price objective on Quotient Limited from $15.00 to $13.00 and set a buy rating for the company in a research note on Wednesday. Zacks Investment Research raised Quotient Limited from a sell rating to a hold rating in a research note on Wednesday, August 9th. Finally, ValuEngine cut Quotient Limited from a sell rating to a strong sell rating in a research note on Friday, September 1st.

Shares of Quotient Limited (NASDAQ:QTNT) remained flat at $$5.13 during midday trading on Wednesday. The stock had a trading volume of 200,043 shares, compared to its average volume of 399,235. Quotient Limited has a 1-year low of $3.22 and a 1-year high of $7.74. The company has a current ratio of 1.36, a quick ratio of 1.71 and a debt-to-equity ratio of -5.17.

Quotient Limited (NASDAQ:QTNT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.55). Quotient Limited had a negative return on equity of 13,050.41% and a negative net margin of 404.29%. The business had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $5.70 million. sell-side analysts predict that Quotient Limited will post -2.1 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/11/05/btig-research-reaffirms-buy-rating-for-quotient-limited-qtnt.html.

In related news, insider D J. Paul E. Cowan sold 100,000 shares of Quotient Limited stock in a transaction on Monday, September 18th. The stock was sold at an average price of $4.41, for a total value of $441,000.00. Following the completion of the transaction, the insider now directly owns 26,666 shares in the company, valued at $117,597.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider D J. Paul E. Cowan sold 30,197 shares of Quotient Limited stock in a transaction on Monday, October 16th. The shares were sold at an average price of $4.92, for a total value of $148,569.24. Following the completion of the transaction, the insider now owns 26,666 shares of the company’s stock, valued at $131,196.72. The disclosure for this sale can be found here. Insiders sold 375,197 shares of company stock valued at $1,639,728 over the last ninety days. Insiders own 29.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in QTNT. New York State Common Retirement Fund purchased a new position in Quotient Limited in the second quarter valued at $101,000. Goldman Sachs Group Inc. purchased a new position in Quotient Limited in the second quarter valued at $104,000. Nationwide Fund Advisors purchased a new position in Quotient Limited in the second quarter valued at $111,000. The Manufacturers Life Insurance Company purchased a new position in Quotient Limited in the second quarter valued at $177,000. Finally, Rhumbline Advisers purchased a new position in Quotient Limited in the second quarter valued at $201,000. Hedge funds and other institutional investors own 57.68% of the company’s stock.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

What are top analysts saying about Quotient Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quotient Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit